Clinical outcomes of haematological patients undergoing bronchoscopy in a registry of immunocompromised patients evaluated for pulmonary infections.
Conclusion: In our centre, adverse events from bronchoscopy were not increased in haematology patients. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Gan, E., Chua, B., Puan, Y. X., Toh, T., Reddy, S. K., Fong, I., Tan, D., Tan, Y. H. Tags: Respiratory infections and bronchiectasis Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Int J Hematol. 2023 Oct 26. doi: 10.1007/s12185-023-03670-3. Online ahead of print.ABSTRACTEltrombopag has been shown to improve response rates when added to standard therapy in adults with severe aplastic anemia in controlled trial settings. However, outcomes in real-world populations have mostly been examined in small retrospective studies. This robust, multicenter, retrospective cohort study across six academic health systems compared outcomes in patients who received immunosuppressive therapy with or without eltrombopag. The study included 82 patients who received front-line therapy from January 2014 to August 2021. Ov...
Source: International Journal of Hematology - October 26, 2023 Category: Hematology Authors: Lauren T Shinn Lydia L Benitez Anthony J Perissinotti Justin H Reid Kaitlyn M Buhlinger Hendrik van Deventer Dylan Barth Charlotte B Wagner Kyle Zacholski Ruchi Desai Ashley Soule Sarah E Stump Taylor M Weis Dale Bixby Patrick Burke Kristen Pettit Bernard Source Type: research
Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma
Oncology (Williston Park). 2023 Oct 10;37(10):419-424. doi: 10.46883/2023.25921006.ABSTRACTPredominantly autoimmune in origin, severe normochromic, normocytic anemia with reticulocytopenia in the setting of the normal production of leukocytes and megakaryocytic lineages is known as pure red cell aplasia (PRCA), which is unlike aplastic anemia in which all lineages are affected due to a stem cell defect. PRCA can be primary (such as autoimmune) or acquired, which can be an acute self-limited illness or a chronic disease that may be induced by medications, including immunotherapy such as monoclonal antibodies (mAbs). Daratum...
Source: Oncology (Williston Park, N.Y.) - October 25, 2023 Category: Cancer & Oncology Authors: Ludovic Saba Kevin S Landau Silvia Bunting Chakra P Chaulagain Source Type: research
